CStone and LegoChem Biosciences enter into global licensing agreement

▴ CStone and LegoChem Biosciences enter into global licensing agreement
This partnership puts LCB71 in a path to development and commercialization for patients around the world

CStone Pharmaceuticals announced a licensing agreement with LegoChem Biosciences, Inc., for the development and marketing of LCB71, a possible first-class / best-in-class antibody drug conjugate ("ADC").

Under the agreement, CStone obtains the exclusive worldwide right to lead the development and commercialization of LCB71 outside the Republic of Korea. LCB will receive an initial payment of US $ 10 million, and up to US $ 353.5 million in accumulated milestone payments, plus basic entitlements.

Frank Jiang , MD, Ph.D., President and CEO of CStone, said: "We are very pleased to form this partnership with LCB, a leading ADC platform company, to obtain global rights to an asset with highly differentiated attributes in an exciting new field of oncology. The agreement adds the first ADC to CStone's development process, and reinforces our precision medicine franchise with a new modality. We look forward to harnessing its full potential and bringing it to patients around the world. "

LCB71 is a preclinical ADC entering New Drug Investigation (IND) allowing studies. It targets ROR1 (Receptor Tyrosine Kinase as Orphan Receptor 1), a high potential ADC target for multiple solid and hematologic malignancies. ROR1 protein expression is prevalent in a variety of cancers, including various forms of leukemia, non-Hodgkin lymphoma, and breast, lung, and ovarian cancers.

LCB71 has a proprietary tumour-activated pyrrolobenzodiazepine ("PBD") prodrug toxin that addresses the typical toxicity problem associated with traditional PBD payloads. It has demonstrated complete tumour inhibition in several preclinical cancer models, which can translate into a broad therapeutic index for a range of solid and hematologic malignancies. In addition, it uses site-specific conjugation for a precise ratio of drug antibodies. This supports the serum half-life and improves its pharmacokinetic profile, and also allows for homogeneous production and large-scale manufacturing.

Dr Yong-Zu Kim, CEO and President of LCB, said: "We are pleased to have reached this agreement with CStone, which has demonstrated extensive experience in oncology, especially in global clinical development. This partnership puts LCB71 in a path to development and commercialization for patients around the world. We are convinced that CStone is the right partner to secure the future of this important drug. "

Tags : #CStonePharmaceuticals #LatestNewsonCStonePharmaceuticals #LegoChemBiosciences #LatestNewsnLegoChemBiosciences29thOct #LatestPharmaCollaboration29thOct #LatestPharmaNews29thOct #Cancers #FrankJiang #RepulicofKorea #DrYong-ZuKim

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

The Surprising Link Between Sleep and Age Perception: What You Need to KnowMarch 29, 2024
The Dark Side of Beauty: Kidney Damage from Hair Straightening TreatmentsMarch 29, 2024
The Dark Side of Beauty: Kidney Damage from Hair Straightening TreatmentsMarch 29, 2024
Avance Clinical at World Vaccine Congress to Share Latest Vaccine Clinical Trial News Including an HIV-1 StudyMarch 29, 2024
Sexual wellness superstore, Love Depot launches digital campaign to deliver every desireMarch 28, 2024
Recharge Your Life: Simple Ways to Boost Your Physical and Mental EnergyMarch 28, 2024
The Neurological Toll of Common Household Chemicals: Insights from Recent ResearchMarch 28, 2024
The Aging Puzzle: Decoding the Mechanisms of AgingMarch 28, 2024
The Double-Edged Sword of Kala-azar Treatment: Shedding Light on Eye ComplicationsMarch 28, 2024
FTCCI Launches Industry-Academia Connect to improve the employability of Engineering Graduates and address the growing demand for Talent in Emerging TechMarch 27, 2024
NTT and Olympus Begin World's First Joint Demonstration Experiment of Cloud Endoscopy SystemMarch 27, 2024
NTT and Olympus Begin World's First Joint Demonstration Experiment of Cloud Endoscopy SystemMarch 27, 2024
2nd Edition of IIFL JITO Ahimsa Run for peace & for non-violence to be held on 31st MarchMarch 27, 2024
Brij Hotels Announced 4 Million in Series A Funding March 27, 2024
Combatting Childhood Sedentariness: The Key to Preventing Premature Vascular DamageMarch 27, 2024
Crucial Findings: Unlocking Paths to Combat Ebola's DevastationMarch 27, 2024
Guarding Against Disease: The Crucial Role of Oral Hygiene in Preventive HealthcareMarch 27, 2024
Sanofi & Cipla announce exclusive distribution partnership to expand reach of CNS portfolio in IndiaMarch 26, 2024
Surmandal's Tribute to the Legends of Hindustani Classical MusicMarch 26, 2024
In Moscow, over 350,000 mammograms have been analyzed using artificial intelligence as part of the compulsory health insurance programMarch 26, 2024